SCLERALIGN
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

SCLERALIGN Trademark

Serial Number: 79323051

SCLERALIGN is a trademark filed by Shenyang Kangende Medical Science and Technology Co., Ltd. on August 12, 2021. The trademark is classified under Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Shenyang Kangende Medical Science and Technology Co., Ltd. (16 trademarks)

Room 606, No.39-1 Chuangxin 2 Road,

Entity Type: 99

Trademark Details

Filing Date

August 12, 2021

Registration Date

Not Registered

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 11, 2024 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Jul 22, 2024 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 21, 2024 FICR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jul 20, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jul 20, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 20, 2023 ABN2
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 5, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 15, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 15, 2023 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 5, 2023 GNFN
FINAL REFUSAL E-MAILED
Jan 5, 2023 GNFR
FINAL REFUSAL WRITTEN
Jan 5, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 1, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 30, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 30, 2022 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Sep 10, 2022 NREP
REFUSAL PROCESSED BY IB
Jun 22, 2022 RFNT
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 4, 2022 ADCH
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 31, 2022 RFCS
REFUSAL PROCESSED BY MPU
May 31, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 22, 2022 RFCR
NON-FINAL ACTION WRITTEN
May 21, 2022 CNRT
ASSIGNED TO EXAMINER
May 13, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 19, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 15, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 14, 2021 REPR